Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 6Terminated 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1Dermatologic 1

Conditions

Melanoma 1Carcinoma, Renal Cell 1

Interventions

Cyclophosphamide 222pembrolizumab 201Carboplatin 173Cisplatin 168Gemcitabine 167Paclitaxel 155Docetaxel 140Bevacizumab 138Rituximab 137Radiotherapy 137Nivolumab 126Dexamethasone 126Capecitabine 103fludarabine 102Pemetrexed 92fludarabine phosphate 91Fluorouracil 91Doxorubicin 85Oxaliplatin 79Etoposide 77Cytarabine 77Bortezomib 76Erlotinib Hydrochloride 74Leucovorin 72Filgrastim 68Lenalidomide 67Calcium Dobesilate 66Irinotecan 65atezolizumab 63Radiation 61

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Has results × incomplete Freund's adjuvant × Clear all
NCT00706992 2015-10-28

Anti-MART-1 F5 Lymphocytes to Treat High-Risk Melanoma Patients

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
50 enrolled 13 charts
Dermatologic

Melanoma

NCT00001703 2014-07-25

Vaccine Therapy With Tumor Specific Mutated VHL Peptides in Adult Cancer Patients With Renal Cell Carcinoma

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
6 enrolled 8 charts
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡